Envoy Medical Reports Q3 2026 Financial Results and Clinical Progress for Acclaim Implant
Envoy Medical (COCH) reported its third-quarter 2026 financial results, highlighting a narrowed net loss of $5.2 million ($0.50 per share) compared to a $7.7 million loss in the prior year period. The company maintains a cash position of $14.6 million, which is earmarked for advancing its pivotal clinical studies and upcoming regulatory submissions. Clinical data for the Acclaim fully implanted cochlear implant showed significant efficacy, with mean CNC word recognition scores improving to 53.2% at 12 months from a 15.2% baseline. All 56 participants in the pivotal trial have surpassed the six-month follow-up milestone, with full 12-month data expected by April 2027. The company has also begun submitting Premarket Approval modules to the FDA. Looking ahead, Envoy is preparing for commercialization by planning facility expansions and increasing headcount. While the Esteem device continues to generate modest revenue, management noted that its classification as a hearing aid rather than a prosthetic limits Medicare coverage, driving the strategic focus toward the Acclaim implant.
Topics: clinical trial results earnings report FDA regulatory filing net loss